Search research articles
Contact Us
Filters
Showing results (721-730 of 747) with videos related to
Page
of 75
Sort By:
Journal of Translational Medicine
|
February 24, 2020
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
Sinead Toomey, Aoife Carr, Mateusz Janusz Mezynski, et al.
Neuron
|
July 4, 2015
Critical Role of Histone Turnover in Neuronal Transcription and Plasticity
Ian Maze, Wendy Wenderski, Kyung-Min Noh, et al.
Oncogene
|
September 29, 2015
INPP4B is an oncogenic regulator in human colon cancer
S T Guo, M N Chi, R H Yang, et al.
BMJ Open Respiratory Research
|
September 11, 2025
Differentiating clinically important interstitial lung abnormalities in lung cancer screening
Brintha Selvarajah, Amyn Bhamani, Mehran Azimbagirad, et al.
Nature
|
March 15, 2019
Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3
Lorna A Farrelly, Robert E Thompson, Shuai Zhao, et al.
Journal of Medicinal Chemistry
|
March 18, 2005
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities
Pratik V Devasthale, Sean Chen, Yoon Jeon, et al.
Nature Communications
|
October 26, 2022
Rescue of deficits by Brwd1 copy number restoration in the Ts65Dn mouse model of Down syndrome
Sasha L Fulton, Wendy Wenderski, Ashley E Lepack, et al.
Gynecologic Oncology
|
February 22, 2021
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee
Jean-Emmanuel Kurtz, Val Gebski, Vladyslav Sukhin, et al.
Lancet (London, England)
|
October 17, 2024
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
Mary McCormack, Gemma Eminowicz, Dolores Gallardo, et al.
Nanotoxicology
|
May 22, 2019
The UCD nanosafety workshop (03 December 2018): towards developing a consensus on safe handling of nanomaterials within the Irish university labs and beyond - a report
Vivien Stuttgen, Hugh E Giffney, Ayana Anandan, et al.
Page
of 75
Search research articles
Search
Showing results (721-730 of 747) with videos related to
Sort By:
Page
of 75
Journal of Translational Medicine
|
February 24, 2020
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
Sinead Toomey, Aoife Carr, Mateusz Janusz Mezynski, et al.
Neuron
|
July 4, 2015
Critical Role of Histone Turnover in Neuronal Transcription and Plasticity
Ian Maze, Wendy Wenderski, Kyung-Min Noh, et al.
Oncogene
|
September 29, 2015
INPP4B is an oncogenic regulator in human colon cancer
S T Guo, M N Chi, R H Yang, et al.
BMJ Open Respiratory Research
|
September 11, 2025
Differentiating clinically important interstitial lung abnormalities in lung cancer screening
Brintha Selvarajah, Amyn Bhamani, Mehran Azimbagirad, et al.
Nature
|
March 15, 2019
Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3
Lorna A Farrelly, Robert E Thompson, Shuai Zhao, et al.
Journal of Medicinal Chemistry
|
March 18, 2005
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities
Pratik V Devasthale, Sean Chen, Yoon Jeon, et al.
Nature Communications
|
October 26, 2022
Rescue of deficits by Brwd1 copy number restoration in the Ts65Dn mouse model of Down syndrome
Sasha L Fulton, Wendy Wenderski, Ashley E Lepack, et al.
Gynecologic Oncology
|
February 22, 2021
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee
Jean-Emmanuel Kurtz, Val Gebski, Vladyslav Sukhin, et al.
Lancet (London, England)
|
October 17, 2024
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
Mary McCormack, Gemma Eminowicz, Dolores Gallardo, et al.
Nanotoxicology
|
May 22, 2019
The UCD nanosafety workshop (03 December 2018): towards developing a consensus on safe handling of nanomaterials within the Irish university labs and beyond - a report
Vivien Stuttgen, Hugh E Giffney, Ayana Anandan, et al.
Page
of 75